- Home
- SKYE vs STG Comparison
SKYE vs STG Comparison
Compare SKYE & STG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- STG
- Stock Information
- Founded
- SKYE 2012
- STG 2003
- Country
- SKYE United States
- STG China
- Employees
- SKYE N/A
- STG N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- STG Other Consumer Services
- Sector
- SKYE Health Care
- STG Real Estate
- Exchange
- SKYE Nasdaq
- STG Nasdaq
- Market Cap
- SKYE 80.7M
- STG 84.9M
- IPO Year
- SKYE N/A
- STG 2018
- Fundamental
- Price
- SKYE $2.43
- STG $5.59
- Analyst Decision
- SKYE Buy
- STG
- Analyst Count
- SKYE 7
- STG 0
- Target Price
- SKYE $18.67
- STG N/A
- AVG Volume (30 Days)
- SKYE 136.4K
- STG 4.1K
- Earning Date
- SKYE 03-21-2025
- STG 03-21-2025
- Dividend Yield
- SKYE N/A
- STG N/A
- EPS Growth
- SKYE N/A
- STG N/A
- EPS
- SKYE N/A
- STG 4.57
- Revenue
- SKYE N/A
- STG $292,030,936.00
- Revenue This Year
- SKYE N/A
- STG N/A
- Revenue Next Year
- SKYE N/A
- STG N/A
- P/E Ratio
- SKYE N/A
- STG $1.22
- Revenue Growth
- SKYE N/A
- STG N/A
- 52 Week Low
- SKYE $2.31
- STG $4.25
- 52 Week High
- SKYE $17.65
- STG $11.06
- Technical
- Relative Strength Index (RSI)
- SKYE 40.00
- STG 38.54
- Support Level
- SKYE $2.40
- STG $4.70
- Resistance Level
- SKYE $2.88
- STG $6.76
- Average True Range (ATR)
- SKYE 0.24
- STG 0.36
- MACD
- SKYE -0.02
- STG -0.12
- Stochastic Oscillator
- SKYE 3.74
- STG 43.20
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.